Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Gains from Sales and Divestitures: 2021-2023

Historic Gains from Sales and Divestitures for Therapeutics (RAPT) over the last 3 years, with Dec 2023 value amounting to $13,500.

  • Therapeutics' Gains from Sales and Divestitures changed negligibly% to $13,500 in Q3 2024 from the same period last year, while for Sep 2024 it was $13,500, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $13,500 for FY2023, which is negligibly% changed negligibly from last year.
  • Per Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $13,500 for FY2023, which was down 0.00% from $13,500 recorded in FY2022.
  • Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $14,125 during FY2021, with a 5-year trough of $13,500 in FY2022.
  • Its 3-year average for Gains from Sales and Divestitures is $13,708, with a median of $13,500 in 2023.
  • Data for Therapeutics' Gains from Sales and Divestitures shows a maximum YoY fell of 4.42% (in 2022) over the last 5 years.
  • Yearly analysis of 3 years shows Therapeutics' Gains from Sales and Divestitures stood at $14,125 in 2021, then fell by 4.42% to $13,500 in 2022, then remained steady at $13,500 in 2023.